Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype*
- 2 April 1997
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 61 (4) , 459-466
- https://doi.org/10.1016/s0009-9236(97)90196-x
Abstract
Codeine is widely used as an analgesic and antitussive drug. The analgesic effect of codeine is mediated by its metabolite morphine, which is formed by the polymorphically expressed enzyme CYP2D6; therefore poor metabolizers have no analgesia after administration of codeine. Like other opiates, codeine causes a delay of gastric emptying and spastic constipation. It is not yet known whether the effect on gastrointestinal motility is mediated by codeine or its metabolite morphine. To test the hypothesis that the metabolite morphine is responsible for the effects of codeine on gastrointestinal motility, a randomized, double-blind, two-way crossover study was performed. The orocecal transit time was studied in five extensive and five poor metabolizers of sparteine with the sulfasalazine-sulfapyridine method, assuming that no effects are observed in poor metabolizers because negligible amounts of morphine are formed. No differences of orocecal transit times were observed between extensive metabolizers and poor metabolizers after oral placebo administration. However, after oral codeine administration orocecal transit time was significantly prolonged in extensive metabolizer but not poor metabolizer subjects. All pharmacokinetic parameters of codeine showed no differences between extensive metabolizers and poor metabolizers. The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol). Because the orocecal transit time prolongation after codeine administration was observed only in extensive metabolizers, the effect of codeine on gastrointestinal motility, like the analgesia, is mediated by its metabolite morphine.Keywords
This publication has 27 references indexed in Scilit:
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Published by Elsevier ,2005
- Nomenclature for human CYP2D6 allelesPharmacogenetics, 1996
- Cloning and sequencing of a new non-functional CYP2D6 allele: Deletion of T1795 in exon 3 generates a premature stop codonPharmacogenetics, 1994
- Quantitative, noninvasive assessment of antidiarrheal actions of codeine using an experimental model of diarrhea in manDigestive Diseases and Sciences, 1993
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- POLYMORPHIC O-DEMETHYLATION OF CODEINEThe Lancet, 1988
- ANALGESIC ACTIVITY OF MORPHINE-6-GLUCURONIDEThe Lancet, 1988
- Effect of codeine and loperamide on upper intestinal transit and absorption in normal subjects and patients with postvagotomy diarrhoea.Gut, 1988
- Studies of the Mechanism of the Antidiarrheal Effect of CodeineJournal of Clinical Investigation, 1982